PCM
REGN icon

Palouse Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Palouse Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
2,479
+145
+6% +$98.7K 0.96% 43
2026
Q1 		$1.8M Sell
2,334
-119
-5% -$91.1K 1.19% 40
2025
Q4 		$1.89M Sell
2,453
-140
-5% -$95.1K 1.21% 37
2025
Q3 		$1.46M Sell
2,593
-104
-4% -$58.8K 0.93% 50
2025
Q2 		$1.42M Buy
+2,697
New +$1.51M 0.93% 49
2024
Q1 		– Sell
-1,286
Closed -$1.13M – 150
2023
Q4 		$1.13M Sell
1,286
-8
-0.6% -$6.59K 0.8% 52
2023
Q3 		$1.06M Buy
1,294
+4
+0.3% +$3.14K 0.79% 54
2023
Q2 		$927K Sell
1,290
-76
-6% -$58.6K 0.65% 60
2023
Q1 		$1.12M Sell
1,366
-397
-23% -$299K 0.76% 56
2022
Q4 		$99.6M Sell
1,763
-553
-24% -$408K 6.89% 1
2022
Q3 		$1.59M Sell
2,316
-68
-3% -$42.8K 0.91% 52
2022
Q2 		$1.41M Sell
2,384
-601
-20% -$391K 0.7% 55
2022
Q1 		$2.08M Sell
2,985
-118
-4% -$74.7K 0.92% 50
2021
Q4 		$1.96M Buy
3,103
+495
+19% +$304K 0.84% 50
2021
Q3 		$1.58M Sell
2,608
-1,122
-30% -$697K 0.7% 55
2021
Q2 		$2.08M Buy
3,730
+50
+1% +$25.3K 0.91% 49
2021
Q1 		$1.74M Buy
+3,680
New +$1.79M 0.77% 52

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Palouse Capital Management's REGN Position: Q2 2026 in Review

Palouse Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 6.2% in Q2 2026, buying an estimated $98.7K and bringing the position to 2,479 shares worth $1.55M. The position accounts for 0.96% of the portfolio, ranked #43.

Palouse Capital Management first reported a position in REGN in Q1 2021 and has held it in 17 quarters since. The position peaked at $99.6M in Q4 2022. 237 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Palouse Capital Management held 2,479 shares of Regeneron Pharmaceuticals worth $1.55M as of Q2 2026.
  • Palouse Capital Management bought 145 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $98.7K.
  • Regeneron Pharmaceuticals made up 0.96% of Palouse Capital Management's portfolio in Q2 2026, its #43 holding.
  • Palouse Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Palouse Capital Management's Regeneron Pharmaceuticals position peaked at $99.6M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Palouse Capital Management's 13F filing for Q2 2026, filed 8 Jul 2026.